vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and Genie Energy Ltd. (GNE). Click either name above to swap in a different company.
Apellis Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($199.9M vs $138.3M, roughly 1.4× Genie Energy Ltd.). Genie Energy Ltd. runs the higher net margin — 4.9% vs -29.5%, a 34.4% gap on every dollar of revenue. On growth, Genie Energy Ltd. posted the faster year-over-year revenue change (23.6% vs -5.9%). Over the past eight quarters, Genie Energy Ltd.'s revenue compounded faster (14.8% CAGR vs 7.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Genie Energy Ltd.GNEEarnings & Financial Report
Genie Energy Ltd. is an American energy company headquartered in Newark, New Jersey. It is a holding company comprising Genie Retail Energy, Genie Retail Energy International, Genie Energy Services, and Genie Energy Oil and Gas. Michael Stein is the Chief Executive Officer, Genie Energy Ltd.
APLS vs GNE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $138.3M |
| Net Profit | $-59.0M | $6.7M |
| Gross Margin | — | 21.7% |
| Operating Margin | -25.6% | 5.0% |
| Net Margin | -29.5% | 4.9% |
| Revenue YoY | -5.9% | 23.6% |
| Net Profit YoY | -62.2% | -33.9% |
| EPS (diluted) | $-0.40 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $138.3M | ||
| Q2 25 | $178.5M | $105.3M | ||
| Q1 25 | $166.8M | $136.8M | ||
| Q4 24 | $212.5M | $102.9M | ||
| Q3 24 | $196.8M | $111.9M | ||
| Q2 24 | $199.7M | $90.7M | ||
| Q1 24 | $172.3M | $119.7M |
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $6.7M | ||
| Q2 25 | $-42.2M | $2.8M | ||
| Q1 25 | $-92.2M | $10.3M | ||
| Q4 24 | $-36.4M | $-15.3M | ||
| Q3 24 | $-57.4M | $10.2M | ||
| Q2 24 | $-37.7M | $9.6M | ||
| Q1 24 | $-66.4M | $8.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 21.7% | ||
| Q2 25 | — | 22.3% | ||
| Q1 25 | — | 27.3% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | — | 33.9% | ||
| Q2 24 | — | 36.8% | ||
| Q1 24 | — | 28.2% |
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 5.0% | ||
| Q2 25 | -18.6% | 1.9% | ||
| Q1 25 | -50.0% | 9.4% | ||
| Q4 24 | -12.3% | -20.2% | ||
| Q3 24 | -24.0% | 10.4% | ||
| Q2 24 | -14.7% | 11.6% | ||
| Q1 24 | -36.0% | 8.2% |
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 4.9% | ||
| Q2 25 | -23.6% | 2.7% | ||
| Q1 25 | -55.3% | 7.5% | ||
| Q4 24 | -17.1% | -14.9% | ||
| Q3 24 | -29.2% | 9.1% | ||
| Q2 24 | -18.9% | 10.6% | ||
| Q1 24 | -38.5% | 6.8% |
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.26 | ||
| Q2 25 | $-0.33 | $0.11 | ||
| Q1 25 | $-0.74 | $0.40 | ||
| Q4 24 | $-0.30 | $-0.58 | ||
| Q3 24 | $-0.46 | $0.38 | ||
| Q2 24 | $-0.30 | $0.36 | ||
| Q1 24 | $-0.54 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $109.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.1M | $198.8M |
| Total Assets | $1.1B | $394.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $109.8M | ||
| Q2 25 | $370.0M | $106.0M | ||
| Q1 25 | $358.4M | $118.3M | ||
| Q4 24 | $411.3M | $110.1M | ||
| Q3 24 | $396.9M | $141.8M | ||
| Q2 24 | $360.1M | $126.8M | ||
| Q1 24 | $325.9M | $106.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $198.8M | ||
| Q2 25 | $156.3M | $197.0M | ||
| Q1 25 | $164.2M | $198.0M | ||
| Q4 24 | $228.5M | $190.5M | ||
| Q3 24 | $237.1M | $211.1M | ||
| Q2 24 | $264.3M | $202.1M | ||
| Q1 24 | $266.7M | $192.9M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $394.1M | ||
| Q2 25 | $821.4M | $383.1M | ||
| Q1 25 | $807.3M | $384.4M | ||
| Q4 24 | $885.1M | $371.3M | ||
| Q3 24 | $901.9M | $341.7M | ||
| Q2 24 | $904.5M | $322.8M | ||
| Q1 24 | $831.9M | $328.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $13.9M |
| Free Cash FlowOCF − Capex | $-14.3M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 2.07× |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $13.9M | ||
| Q2 25 | $4.4M | $1.1M | ||
| Q1 25 | $-53.4M | $15.3M | ||
| Q4 24 | $19.4M | $13.0M | ||
| Q3 24 | $34.1M | $24.4M | ||
| Q2 24 | $-8.3M | $20.4M | ||
| Q1 24 | $-133.0M | $12.9M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | $13.6M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $21.9M | ||
| Q2 24 | $-8.4M | $20.1M | ||
| Q1 24 | $-133.3M | $11.7M |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | 9.9% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | 19.6% | ||
| Q2 24 | -4.2% | 22.1% | ||
| Q1 24 | -77.3% | 9.8% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.2% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.07× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.39× | ||
| Q2 24 | — | 2.12× | ||
| Q1 24 | — | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GNE
| Sales Channel Directly To Consumer | $108.8M | 79% |
| Sales Channel Through Intermediary | $23.5M | 17% |
| Genie Renewables GREW | $6.0M | 4% |
